natgillin/translations-raw huggingface dataset:
If any patient develops symptoms suggesting hepatic dysfunction, which may include unexplained nausea, vomiting, abdominal pain, fatigue, anorexia and/or dark urine, liver enzymes should be checked. 
Če se pri bolniku pojavijo simptomi, ki kažejo na moteno delovanje jeter, med njimi so lahko nepojasnjena navzea, bruhanje, bolečina v trebuhu, utrujenost, anoreksija in/ali temen urin, je treba preveriti jetrne encime.
Almost all subjects (95%) were receiving cardiovascular medicinal products (beta blockers, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II antagonists, calcium channel blockers, nitrates, diuretics, aspirin, statins, fibrates). 
Skoraj vsi vključeni bolniki (95 %) so prejemali kardiovaskularna zdravila (zaviralci adrenergičnih receptorjev beta, zaviralci angiotenzinske konvertaze (ACE), antagonisti angiotenzina II, zaviralci kalcijevih kanalčkov, nitrati, diuretiki, acetilsalicilna kislina, statini, fibrati).
Results from alogliptin studies with metformin, pioglitazone (thiazolidinedione), voglibose (alphaglucosidase inhibitor) and glyburide (sulphonylurea) have shown no clinically relevant pharmacokinetic interactions. 
Rezultati študij z metforminom, s pioglitazonom (tiazolidindion), z voglibozo (zaviralec glukozidaze alfa) in gliburidom (sulfonilsečnina) ne kažejo klinično pomembnih farmakokinetičnih interakcij.
A 24-month mechanistic study in male rats demonstrated that administration of pioglitazone resulted in an increased incidence of hyperplastic changes in the bladder. 
24-mesečna študija mehanizma pri samcih podgan je pokazala, da se pri uporabi pioglitazona poveča pojavnost hiperplastičnih sprememb v sečnem mehurju.
When treating patients who have at least one risk factor for development of congestive heart failure (e.g. prior myocardial infarction or symptomatic coronary artery disease or the elderly), physicians should start pioglitazone therapy with the lowest available dose and increase the dose gradually. 
Pri zdravljenju bolnikov z vsaj enim dejavnikom tveganja za razvoj kongestivnega srčnega popuščanja (npr. predhodni miokardni infarkt, simptomatska bolezen koronarnih arterij ali višja starost) je treba zdravljenje s pioglitazonom uvesti v najmanjšem možnem odmerku in ga postopno povečevati.
In addition, a prospective randomised cardiovascular outcomes safety study was conducted with 5,380 patients with high underlying cardiovascular risk to examine the effect of alogliptin compared with placebo (when added to standard of care) on major adverse cardiovascular events (MACE) including time to the first occurrence of any event in the composite of cardiovascular death, nonfatal myocardial infarction and nonfatal stroke in patients with a recent (15 to 90 days) acute coronary event. 
Poleg tega pa je bila izvedena tudi prospektivna randomizirana študija izidov kardiovaskularne varnosti, v katero je bilo vključenih 5.380 bolnikov z velikim osnovnim kardiovaskularnim tveganjem za ovrednotenje učinka alogliptina v primerjavi s placebom (kot dodatek k standardnemu zdravljenju) na pomembne neželene kardiovaskularne dogodke (MACE, “major adverse cardiovascular events”), vključno s časom do prvega pojava katerega koli dogodka, sestavljenega iz kardiovaskularne smrti, neusodnega miokardnega infarkta in neusodne možganske kapi pri bolnikih z nedavnim (15 do 90 dni) akutnim koronarnim dogodkom.
Risk factors for bladder cancer should be assessed before initiating Incresync treatment (risks include age, smoking history, exposure to some occupational or chemotherapy medicinal products e.g. cyclophosphamide or prior radiation treatment in the pelvic region). 
Pred uvedbo zdravljenja z zdravilom Incresync je treba oceniti dejavnike tveganja za rak sečnega mehurja (tveganja vključujejo starost, kajenje v anamnezi, poklicna izpostavljenost nekaterim dejavnikom ali izpostavljenost kemoterapevtikom, npr. ciklofosfamidu, ali predhodno zdravljenje z obsevanjem v predelu medenice).
In case of hypoglycaemia, a lower dose of the thiazolidinedione or metformin may be considered. 
V primeru pojava hipoglikemije je treba razmisliti o zmanjšanju odmerka tiazolidindiona ali metformina.
The pharmacokinetics of alogliptin has been shown to be similar in healthy subjects and in patients with type 2 diabetes mellitus. 
Dokazano je bilo, da je farmakokinetika alogliptina pri zdravih osebah in bolnikih s sladkorno boleznijo tipa 2 podobna.
If a dose is missed, it should be taken as soon as the patient remembers. 
Če bolnik pozabi vzeti odmerek zdravila, ga mora vzeti takoj, ko se spomni.
In patients who fail to show an adequate response, Incresync should be discontinued. 
Pri bolnikih, pri katerih ni zadovoljivega odziva, je treba zdravljenje z zdravilom Incresync ukiniti.
Alogliptin is primarily excreted unchanged in the urine and metabolism by the cytochrome (CYP) P450 enzyme system is negligible (see section 5.2). 
Alogliptin se primarno izloča z urinom v nespremenjeni obliki, presnova z encimskim sistemom citokroma (CYP - cytochrome) P450 pa je zanemarljiva (glejte poglavje 5.2).
Alogliptin was not genotoxic in a standard battery of in vitro and in vivo genotoxicity studies. 
Alogliptin ni bil genotoksičen v standardnem naboru študij genotoksičnosti in vitro ter in vivo.
The majority of these episodes were mild to moderate in intensity. 
Večina epizod hipoglikemije je bila blagih do zmernih.
Visual disturbance has been reported mainly early in treatment and is related to changes in blood glucose due to temporary alteration in the turgidity and refractive index of the lens as seen with other hypoglycaemic treatments. 
O motnjah vida so večinoma poročali kmalu po uvedbi zdravljenja, povezane pa so s spremembami vrednosti glukoze v krvi, in sicer zaradi začasnih sprememb turgidnosti in refrakcijskega indeksa leče, kakršne se pojavljajo tudi pri drugih antidiabetikih.
If jaundice is observed, the medicinal product should be discontinued. 
Če se pojavi zlatenica, je treba zdravljenje z zdravilom prekiniti.
Since insulin and pioglitazone are both associated with fluid retention, concomitant administration may increase the risk of oedema. 
Ker sta tako insulin kot pioglitazon povezana z zastajanjem tekočine, se lahko pri njuni sočasni uporabi poveča tveganje za razvoj edemov.
GLP-1 and GIP increases insulin biosynthesis and secretion from pancreatic beta cells, while GLP-1 also inhibits glucagon secretion and hepatic glucose production. 
GLP-1 in GIP povečujeta biosintezo insulina in izločanje iz beta celic trebušne slinavke, GLP-1 pa tudi zavira izločanje glukagona in tvorbo glukoze v jetrih.
Studies in vitro have shown alogliptin to be a mild inducer of CYP3A4, but alogliptin has not been shown to induce CYP3A4 in studies in vivo. 
Študije in vitro so pokazale, da je alogliptin blag induktor CYP3A4, vendar pa pri študijah in vivo alogliptin ni induciral CYP3A4.
The effect of pioglitazone (45 mg monotherapy vs. placebo) was studied in a small 18-week study in type 2 diabetics. 
Vpliv pioglitazona (45 mg v monoterapiji v primerjavi s placebom) so raziskali v majhni, 18-tedenski študiji pri bolnikih s sladkorno boleznijo tipa 2.
- Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis). 
• Huda in trdovratna bolečina v trebuhu (v predelu želodca), ki lahko izžareva v hrbet, pa tudi siljenje na bruhanje in bruhanje, so lahko znak vnetja trebušne slinavke (pankreatitisa).
In the prospective randomised controlled cardiovascular outcomes study, investigator reported events of hypoglycemia were similar in patients receiving placebo (6.5%) and patients receiving alogliptin (6.7%) in addition to standard of care. 
V prospektivni randomizirani nadzorovani študiji kardiovaskularnih izidov so raziskovalci poročali o podobni pojavnosti hipoglikemičnih dogodkov pri bolnikih, ki so poleg standardnega zdravljenja prejemali placebo (6,5 %) in bolnikih, ki so prejemali alogliptin (6,7 %).
Combination of alogliptin with other anti-diabetic medicinal products 
Kombinacije alogliptina z drugimi antidiabetiki
Neoplasms benign, malignant and unspecified (including cysts and polyps) bladder cancer uncommon 
Benigne, maligne in neopredeljene novotvorbe (vključno s cistami in polipi) rak sečnega mehurja občasni
In studies in vitro, alogliptin was not an inhibitor of the following renal transporters; OAT1, OAT3 and OCT2. 
Pri študijah in vitro alogliptin ni zaviral ledvičnih prenašalcev OAT1, OAT3 in OCT2.
For patients switching from separate tablets of alogliptin and pioglitazone, both alogliptin and pioglitazone should be dosed at the daily dose already being taken. 
Pri bolnikih, ki prehajajo z ločenih tablet alogliptina in pioglitazona, je treba tako odmerek alogliptina kot odmerek pioglitazona določiti na osnovi dnevnega odmerka, ki ga že jemljejo.
It is unclear whether or not there is a direct association between pioglitazone and macular oedema but prescribers should be alert to the possibility of macular oedema if patients on Incresync report disturbances in visual acuity; an appropriate ophthalmological referral should be considered. 
Ni jasno, če obstaja neposredna povezava med uporabo pioglitazona in razvojem makularnega edema, vendar pa morajo biti zdravniki pozorni na možnost makularnega edema, če bolnik, ki se zdravi z zdravilom Incresync, navaja težave z ostrino vida.
Nylon/aluminium/polyvinyl chloride (PVC) blisters with push through aluminium lidding foil. 
Pretisni omoti iz najlona/aluminija/polivinil klorida (PVC - polyvinyl chloride), prekriti z aluminijasto pretisno folijo.
Clinically meaningful reductions in HbA1c compared to placebo were also observed with 25 mg alogliptin regardless of whether patients were receiving concomitant metformin or sulphonylurea therapy. 
Klinično pomembna znižanja vrednosti HbA1c v primerjavi s placebom so bila opažena tudi pri uporabi alogliptina v odmerku 25 mg ne glede na to, ali so se bolniki sočasno zdravili z metforminom ali s sulfonilsečnino.
In studies in vitro, alogliptin was found to be neither a substrate nor an inhibitor of key transporters associated with disposition of the active substance in the kidney: organic anion transporter-1, organic anion transporter-3 or organic cationic transporter-2 (OCT2). 
V študijah in vitro je bilo ugotovljeno, da alogliptin ni niti substrat niti zaviralec ključnih prenašalcev, povezanih z odlaganjem učinkovine v ledvicah: organskega anionskega prenašalca-1, organskega anionskega prenašalca-3 ali organskega kationskega prenašalca-2 (OCT2; “organic cationic transporter-2”).
In animal fertility studies conducted with pioglitazone there was no effect on copulation, impregnation or fertility index. 
Pri študijah plodnosti pri živalih, izvedenih s pioglitazonom, niso opazili vplivov na parjenje, oploditev ali indeks plodnosti.
A single dose of 50 mg alogliptin was administered to 4 groups of patients with varying degrees of renal impairment (CrCl using the Cockcroft-Gault formula): mild (CrCl = > 50 to ≤ 80 mL/min), moderate (CrCl = ≥ 30 to ≤ 50 mL/min), severe (CrCl = < 30 mL/min) and end-stage renal disease on haemodialysis. 
Enkratni odmerek 50 mg alogliptina so prejele 4 skupine bolnikov z različno stopnjo okvare ledvic (CrCl po enačbi Cockcroft-Gault): blaga (CrCl = > 50 do ≤ 80 ml/min), zmerna (CrCl = ≥ 30 do ≤ 50 ml/min), huda (CrCl = <30 ml/min) in končna ledvična odpoved na hemodializi.
M-I is an active metabolite and is a highly selective inhibitor of DPP-4 similar to alogliptin; M-II does not display any inhibitory activity towards DPP-4 or other DPP-related enzymes. 
M-I je aktiven presnovek in zelo selektiven zaviralec DPP-4, podobno kot alogliptin, M-II pa ne kaže zaviralne aktivnosti v razmerju do DPP-4 ali drugih encimov, sorodnih DPP.
Alogliptin was not teratogenic in rats or rabbits with a systemic exposure at the NOAELs far above the human exposure at the recommended dose. 
Alogliptin ni bil teratogen pri podganah in kuncih pri sistemski izpostavljenosti s stopnjami NOAEL, ki so bile veliko večje od izpostavljenosti človeka pri priporočenem odmerku.
To be eligible, patients had to have had one or more of the following: myocardial infarction, stroke, percutaneous cardiac intervention or coronary artery bypass graft, acute coronary syndrome, coronary artery disease, or peripheral arterial obstructive disease. 
Da bi bolniki ustrezali merilom za vključitev v študijo, so morali v anamnezi imeti enega ali več naslednjih dejavnikov ali stanj: miokardni infarkt, možgansko kap, perkutani poseg na srcu ali obvodno operacijo koronarnih arterij, akutni koronarni sindrom, bolezen koronarnih arterij ali obstruktivno bolezen perifernih arterij.
Intrinsic clearance is, therefore, reduced coupled with a higher unbound fraction of pioglitazone (see section 4.2). 
Intrinzični očistek je torej manjši ob sočasnem večjem deležu nevezanega pioglitazona (glejte poglavje 4.2).
Patients should be observed for signs and symptoms of heart failure, weight gain or oedema; particularly those with reduced cardiac reserve. 
Bolnike je treba nadzirati glede pojava znakov in simptomov srčnega popuščanja, povečanja telesne mase ali edemov, še posebej bolnike z zmanjšano srčno rezervo.
Post marketing cases of peripheral oedema and cardiac failure have also been reported in patients with concomitant use of pioglitazone and nonsteroidal anti-inflammatory drugs (NSAIDs), including selective COX-2 inhibitors. 
V obdobju trženja so o primerih perifernega edema in srčnega popuščanja poročali tudi pri bolnikih, ki so se sočasno zdravili s pioglitazonom in z nesteroidnimi protivnetnimi zdravili (NSAIDs - nonsteroidal anti-inflammatory drugs), vključno s selektivnimi zaviralci COX-2.
The fracture incidence calculated was 1.9 fractures per 100 patient years in women treated with pioglitazone and 1.1 fractures per 100 patient years in women treated with a comparator. 
Izračunana pojavnost zlomov je bila 1,9 zloma na 100 bolnikov-let pri ženskah, zdravljenih s pioglitazonom, in 1,1 zloma na 100 bolnikov-let pri ženskah, zdravljenih s primerjalnim zdravilom.
The maximum recommended daily dose of 25 mg alogliptin and 45 mg pioglitazone should not be exceeded. 
Največji priporočeni dnevni odmerek Največjih priporočenih dnevnih odmerkov 25 mg alogliptina in 45 mg pioglitazona se ne sme preseči.
Higher doses of alogliptin decreased offspring body weight and exerted some developmental effects considered secondary to the low body weight. 
Večji odmerki alogliptina so zmanjšali telesno maso mladičev in izkazali določene vplive na razvoj, ki so bili ocenjeni kot posledica majhne telesne mase.
For patients with mild renal impairment (creatinine clearance (CrCl) > 50 to ≤ 80 mL/min), no dose adjustment of Incresync is necessary (see section 5.2). 
Pri bolnikih z blago okvaro ledvic (kreatininski očistek (CrCl - creatinine clearance) > 50 do ≤ 80 ml/min) odmerka zdravila Incresync ni treba prilagajati (glejte poglavje 5.2).
- if you have or have had a disease of the pancreas. 
• če imate ali ste kdaj imeli bolezen trebušne slinavke.
Incresync tablets contain lactose. 
Tablete zdravila Incresync vsebujejo laktozo.
However, as the distribution of AUC values for alogliptin in these patients was within the same range as control subjects, no dose adjustment of alogliptin for patients with mild renal impairment is necessary (see section 4.2). 
Ker pa je bila porazdelitev vrednosti AUC alogliptina pri teh bolnikih v enakem razponu kot pri kontrolnih osebah, pri bolnikih z blago okvaro ledvic odmerka alogliptina ni treba prilagajati (glejte poglavje 4.2).
Steady-state pharmacokinetics is similar in patients aged 65 years and over and young subjects (see section 4.2). 
Farmakokinetika v stanju dinamičnega ravnovesja je pri bolnikih, starih 65 let ali starejših, podobna kot pri mlajših osebah (glejte poglavje 4.2).
Combination treatment with alogliptin and pioglitazone to pregnant rats slightly augmented pioglitazone-related foetal effects of growth retardation and visceral variations, but did not induce embryo-foetal mortality or teratogenicity. 
Kombinirano zdravljenje z alogliptinom in pioglitazonom je pri brejih podganah povzročilo rahel porast s pioglitazonom povezanih učinkov za plod v obliki zaostanka rasti in visceralnih variacij, ni pa povzročilo umrljivosti zarodkov/plodov ali teratogenosti.
Alogliptin works to increase the levels of insulin in the body after a meal and decrease the amount of sugar in the body. 
Alogliptin deluje tako, da po obroku v telesu zviša koncentracijo insulina in zmanjša količino sladkorja.
Cases of bladder cancer were reported more frequently in a meta-analysis of controlled clinical studies with pioglitazone (19 cases from 12,506 patients, 0.15%) than in control groups (7 cases from 10,212 patients, 0.07%) HR=2.64 (95% CI 1.11-6.31, P=0.029). 
V meta-analizi nadzorovanih kliničnih študij so o raku sečnega mehurja poročali pogosteje pri bolnikih, ki so prejemali pioglitazon (19 primerov od 12.506 bolnikov, 0,15 %) kot pri bolnikih v kontrolnih skupinah (7 primerov od 10.212 bolnikov, 0,07 %), HR=2,64 (95 % IZ 1,11-6,31, P=0,029).
The safety and efficacy of Incresync in children and adolescents < 18 years old have not been established. 
Varnost in učinkovitost zdravila Incresync pri otrocih in mladostnikih, mlajših od 18 let, nista bili dokazani.
The maximum recommended daily dose is one 25 mg/45 mg tablet. 
Največji priporočeni dnevni odmerek je ena tableta 25 mg/45 mg.
Studies in man suggest no induction of the main inducible cytochrome P450, 1A, 2C8/9 and 3A4. 
Študije pri ljudeh ne kažejo indukcije glavnih inducibilnih izoencimov citokroma P450, 1A, 2C8/9 in 3A4.
Hepatic impairment Incresync must not be used in patients with hepatic impairment (see sections 4.3, 4.4 and 5.2). 
Okvara jeter Pri bolnikih z okvaro jeter se zdravila Incresync ne sme uporabljati (glejte poglavja 4.3, 4.4 in 5.2).
Following oral administration of radiolabelled pioglitazone to man, recovered label was mainly in faeces (55%) and a lesser amount in urine (45%). 
Pri človeku se je po peroralni uporabi z radioaktivnim izotopom označenega pioglitazona večina radioaktivnosti izločila z blatom (55 %), manjša količina pa z urinom (45 %).
Hypersensitivity to the active substances or to any of the excipients listed in section 6.1 or history of a serious hypersensitivity reaction, including anaphylactic reaction, anaphylactic shock, and angioedema, to any dipeptidyl-peptidase-4 (DPP-4) inhibitor (see sections 4.4 and 4.8) 
• Preobčutljivost na zdravilni učinkovini ali katero koli pomožno snov, navedeno v poglavju 6.1, ali anamneza hude preobčutljivostne reakcije, vključno z anafilaktično reakcijo, anafilaktičnim šokom in angioedemom po uporabi katerega koli zaviralca dipeptidil-peptidaze (DDP-4 - dipeptidyl-peptidase) (glejte poglavji 4.4 in 4.8).
Incresync should be used with caution during concomitant administration of cytochrome P450 2C8 inhibitors (e.g. gemfibrozil) or inducers (e.g. rifampicin). 
Zdravilo Incresync je treba uporabljati previdno pri sočasnem zdravljenju z zaviralci citokroma P450 2C8 (npr. gemfibrozil) ali njegovimi induktorji (npr. rifampicin).
Incresync combines two antihyperglycaemic medicinal products with complementary and distinct mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: alogliptin, a dipeptidyl-peptidase-4 (DPP-4) inhibitor, and pioglitazone, a member of the thiazolidinedione class. 
Zdravilo Incresync je kombinacija dveh antihiperglikemičnih zdravil s komplementarnim in ločenim mehanizmom delovanja, namenjeno za izboljšanje urejenosti glikemije pri bolnikih s sladkorno boleznijo tipa 2: alogliptina, zaviralca dipeptidil-peptidaze-4 (DPP-4) in pioglitazona, ki spada v skupino tiazolidindionov.
Incresync is taken when your blood sugar cannot be adequately controlled by diet, exercise and other oral anti-diabetic medicines such as pioglitazone; or pioglitazone and metformin taken together. 
Zdravilo Incresync uporabljamo, če krvnega sladkorja ni mogoče dovolj dobro nadzorovati z dieto, s telesno vadbo in z drugimi peroralnimi zdravili za zdravljenje sladkorne bolezni, kot so pioglitazon ali pioglitazon in metformin, ki se ju jemlje skupaj.
Interactions with pioglitazone 
Medsebojno delovanje s pioglitazonom
No information is available on pioglitazone and alogliptin use in dialysed patients and, therefore, co-administered alogliptin plus pioglitazone should not be used in such patients (see sections 4.2 and 5.2). 
Pri bolnikih, ki se zdravijo z dializo, podatki o uporabi pioglitazona in alogliptina niso na voljo, zato se alogliptina skupaj s pioglitazonom pri takih bolnikih ne sme uporabljati (glejte poglavji 4.2 in 5.2).
Pioglitazone dose adjustment within the recommended posology or changes in diabetic treatment should be considered (see section 4.5). 
Morda bo treba prilagoditi odmerek pioglitazona v okviru priporočenega odmerjanja ali spremeniti zdravljenje sladkorne bolezni (glejte poglavje 4.5).
Hypersensitivity reactions, including Stevens-Johnson syndrome, anaphylactic reactions, and angioedema are serious and are attributed to the alogliptin component of Incresync (see section 4.4). 
Preobčutljivostne reakcije, vključno s Stevens-Johnsonovim sindromom, anafilaktičnimi reakcijami in angioedemom, so resne in je mogoče pripisati vsebnosti alogliptina v zdravilu Incresync (glejte poglavje 4.4).
In clinical studies with pioglitazone, the incidence of elevations of ALT greater than three times the upper limit of normal was equal to placebo but less than that seen in metformin or sulphonylurea comparator groups. 
V kliničnih študijah s pioglitazonom je bila pojavnost zvišanj vrednosti ALT na več kot trikratno zgornjo mejo normalnih vrednosti enaka kot pri placebu, a manjša kot v primerjalnih skupinah z metforminom ali s sulfonilsečnino.
- A severe allergic reaction: skin lesions or spots on your skin that can progress to a sore surrounded by pale or red rings, blistering and/or peeling of the skin possibly with symptoms such as itching, fever, overall ill feeling, achy joints, vision problems, burning, painful or itchy eyes and mouth sores (Stevens-Johnson syndrome and Erythema multiforme). 
• Huda alergijska reakcija: pojav kožnih sprememb ali lis na koži, ki lahko napredujejo do razjed, obdanih z bledimi ali rdečimi obročki, spremljajo pa jih lahko simptomi, kot so srbenje, zvišana telesna temperatura, splošno slabo počutje, bolečine v sklepih, težave z vidom, pekoče, boleče ali srbeče oči in razjede v ustih (Stevens-Johnsonov sindrom in multiformni eritem).
Caution should be exercised in patients with a history of pancreatitis. 
Pri bolnikih z anamnezo pankreatitisa je potrebna previdnost.
- if you have liver disease. 
• če imate bolezen jeter.
Interaction studies have shown that pioglitazone has no relevant effect on either the pharmacokinetics or pharmacodynamics of digoxin, warfarin, phenprocoumon or metformin. 
Študije medsebojnega delovanja so pokazale, da pioglitazon nima pomembnih učinkov na farmakokinetiko ali farmakodinamiko digoksina, varfarina, fenprokumona ali metformina.
The improved glycaemic control is associated with a reduction in both fasting and postprandial plasma insulin concentrations. 
Boljša urejenost glikemije je povezana z zmanjšanjem koncentracije insulina v plazmi tako na tešče kot po obroku.
In an outcome study of patients with pre-existing major macrovascular disease, the incidence of serious heart failure was 1.6% higher with pioglitazone than with placebo when added to therapy that included insulin. 
V študiji izidov pri bolnikih s predhodno obstoječo hudo makrovaskularno boleznijo je bila pojavnost hudega srčnega popuščanja pri dodatku pioglitazona k zdravljenju, ki je vključevalo insulin, za 1,6 % večja kot pri dodatku placebu.
Your doctor will check whether Incresync is working 3 to 6 months after you start taking it. 
Zdravnik bo 3 do 6 mesecev po uvedbi zdravljenja preveril, če je zdravljenje z zdravilom Incresync učinkovito.